Heat shock protein 90 inhibition attenuates inflammation in models of atopic dermatitis: a novel mechanism of action
Open Access
- 11 January 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1289788
Abstract
Background: Heat shock protein 90 (HSP90) is an important chaperone supporting the function of many proinflammatory client proteins. Recent studies indicate HSP90 inhibition may be a novel mechanism of action for inflammatory skin diseases; however, this has not been explored in atopic dermatitis (AD).Objectives: Our study aimed to investigate HSP90 as a novel target to treat AD.Methods: Experimental models of AD were used including primary human keratinocytes stimulated with cytokines (TNF/IFNγ or TNF/IL-4) and a mouse model established by MC903 applications.Results: In primary human keratinocytes using RT-qPCR, the HSP90 inhibitor RGRN-305 strongly suppressed the gene expression of Th1- (TNF, IL1B, IL6) and Th2-associated (CCL17, CCL22, TSLP) cytokines and chemokines related to AD. We next demonstrated that topical and oral RGRN-305 robustly suppressed MC903-induced AD-like inflammation in mice by reducing clinical signs of dermatitis (oedema and erythema) and immune cell infiltration into the skin (T cells, neutrophils, mast cells). Interestingly, topical RGRN-305 exhibited similar or slightly inferior efficacy but less weight loss compared with topical dexamethasone. Furthermore, RNA sequencing of skin biopsies revealed that RGRN-305 attenuated MC903-induced transcriptome alterations, suppressing genes implicated in inflammation including AD-associated cytokines (Il1b, Il4, Il6, Il13), which was confirmed by RT-qPCR. Lastly, we discovered using Western blot that RGRN-305 disrupted JAK-STAT signaling by suppressing the activity of STAT3 and STAT6 in primary human keratinocytes, which was consistent with enrichment analyses from the mouse model.Conclusion: HSP90 inhibition by RGRN-305 robustly suppressed inflammation in experimental models mimicking AD, proving that HSP90 inhibition may be a novel mechanism of action in treating AD.Keywords
This publication has 50 references indexed in Scilit:
- Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg functionMucosal Immunology, 2013
- Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosusCellular & Molecular Immunology, 2012
- STAT3 interacts directly with Hsp90IUBMB Life, 2012
- EC144, a Synthetic Inhibitor of Heat Shock Protein 90, Blocks Innate and Adaptive Immune Responses in Models of Inflammation and AutoimmunityThe Journal of Immunology, 2011
- Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cellsJournal of Biomedical Science, 2010
- HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cellsCell Communication and Signaling, 2009
- Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritisArthritis & Rheumatism, 2008
- HSP70i Accelerates Depigmentation in a Mouse Model of Autoimmune VitiligoJournal of Investigative Dermatology, 2008
- Atopic DermatitisNew England Journal of Medicine, 2008
- The heat‐shock protein 90 inhibitor 17‐allylamino‐17‐demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitisJournal of Neurochemistry, 2006